{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:05:26Z","timestamp":1787371526133,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency (activity &amp;lt;10%). Urgent intervention based on the timely evaluation of ADAMTS13 level is crucial to guide optimal therapy. The recently developed PLASMIC score based on seven items allows the rapid identification of patients at high risk for TTP due to severe ADAMTS13 deficiency. This retrospective study included 31 hospitalized patients with suspicious thrombotic microangiopathy in National Cheng Kung University Hospital from December 2016 to July 2021. Data on ADAMTS13 activity and medical and laboratory information were retrieved from medical records. The PLASMIC score could be calculated in 24 of the 31 patients with available data, and the final cohort was stratified according to the 7-point PLASMIC score. All patients with high PLASMIC score (6\u20137) exhibited severe ADAMTS13 deficiency (activity \u226410%). One patient with a brain tumor and a PLASMIC score of 6 did not have severe ADAMTS13 activity of \u226410%. The patients in the intermediate- and low risk groups (PLASMIC scores of 5 and 0\u20134, respectively) exhibited ADAMTS13 activities of above 10%. Given the role of prompt diagnosis in the timely delivery of appropriate therapy, these findings confirm and strengthen the predictive value of the PLASMIC score in patients at high risk for TTP due to severe ADAMTS13 deficiency.<\/jats:p>","DOI":"10.3389\/fmed.2022.893273","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T06:32:30Z","timestamp":1652077950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan"],"prefix":"10.3389","volume":"9","author":[{"given":"Chun-Hui","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Syue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","first-page":"21","article-title":"Hyaline thrombosis of the ternimal arterioles and capillaries: a hitherto undescribed disease.","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/asheducation-2015.1.631","article-title":"What\u2019s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.","volume":"2015","author":"Sadler","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"Von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/beha.2001.0142","article-title":"Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von willebrand factor-cleaving protease.","volume":"14","author":"Furlan","year":"2001","journal-title":"Best Pract Res Clin Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-0031-1300951","article-title":"Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and adamts-13.","volume":"38","author":"Chapman","year":"2012","journal-title":"Semin Thromb Hemost."},{"key":"B6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/s2352-3026(17)30026-1","article-title":"Derivation and external validation of the plasmic score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the plasmic score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment.","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/vox.12050","article-title":"Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.","volume":"105","author":"Bentley","year":"2013","journal-title":"Vox Sang."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/s2352-3026(17)30024-8","article-title":"The plasmic score for thrombotic thrombocytopenic purpura.","volume":"4","author":"Jamme","year":"2017","journal-title":"Lancet Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.htct.2018.10.002","article-title":"Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country.","volume":"41","author":"Oliveira","year":"2019","journal-title":"Hematol Transfus Cell Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group.","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura.","volume":"129","author":"Joly","year":"2017","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"Isth guidelines for treatment of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura.","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s11239-018-1674-6","article-title":"Validation of plasmic score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.","volume":"46","author":"Tiscia","year":"2018","journal-title":"J Thromb Thrombolysis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the plasmic score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion."},{"key":"B21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4274\/tjh.galenos.2020.2020.0348","article-title":"Comparison of clinical scoring systems in the management of patients with microangiopathic hemolytic anemia and thrombocytopenia.","volume":"38","author":"Baysal","year":"2021","journal-title":"Turk J Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0037-1603100","article-title":"Clinical scoring systems in thrombotic microangiopathies.","volume":"43","author":"Bendapudi","year":"2017","journal-title":"Semin Thromb Hemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1160\/TH08-12-0825","article-title":"heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.","volume":"102","author":"Matsuyama","year":"2009","journal-title":"Thromb Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0961203308094360","article-title":"Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study.","volume":"18","author":"Kwok","year":"2009","journal-title":"Lupus."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0049-0172(98)80023-1","article-title":"Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus.","volume":"28","author":"Musio","year":"1998","journal-title":"Semin Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10067-013-2312-5","article-title":"Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011.","volume":"33","author":"Jiang","year":"2014","journal-title":"Clin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10067-003-0742-1","article-title":"Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review.","volume":"22","author":"Hamasaki","year":"2003","journal-title":"Clin Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","article-title":"Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.","volume":"2018","author":"Dane","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1182\/blood.2019000795","article-title":"Adjuvant low-dose rituximab and plasma exchange for acquired TTP.","volume":"134","author":"Zwicker","year":"2019","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jca.21760","article-title":"A modified plasmic score including the lactate dehydrogenase\/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original plasmic score.","volume":"35","author":"Zhao","year":"2020","journal-title":"J Clin Apher."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.893273\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T06:32:33Z","timestamp":1652077953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.893273\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":31,"alternative-id":["10.3389\/fmed.2022.893273"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.893273","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"893273"}}